In a report released today, Bill Sutherland from Benchmark Co. initiated coverage with a Buy rating on Agilon Health (AGL – Research Report) and a price target of $13.00. The company’s shares closed last Friday at $8.63.
Sutherland covers the Healthcare sector, focusing on stocks such as Agilon Health, Cross Country Healthcare, and Surgery Partners. According to TipRanks, Sutherland has an average return of -9.5% and a 38.19% success rate on recommended stocks.
Agilon Health has an analyst consensus of Moderate Buy, with a price target consensus of $13.38, which is a 55.04% upside from current levels. In a report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $16.00 price target.
See the top stocks recommended by analysts >>
Based on Agilon Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.22 billion and a GAAP net loss of $31.44 million. In comparison, last year the company earned a revenue of $694.86 million and had a GAAP net loss of $30.67 million
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agilon Health (AGL) Company Description:
Agilon Health Inc is transforming healthcare by empowering community-based physicians with the resources and expertise they need to innovate the payment and delivery of care for seniors. The company enables physicians to create their own Medicare-centric globally capitated line of business.
Read More on AGL:
